[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunitybio Inc (IBRX)

Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

ImmunityBio's Commercial Ramp Now Carries the Weight of Its Entire Investment Thesis

ImmunityBio Inc (IBRX) is scheduled to report first-quarter 2026 earnings on May 11, 2026, with analysts expecting a loss of $0.08 per share. The biotech company faces a critical test as investors assess whether its recent commercial momentum can continue following a disappointing Q1 miss that broke a two-quarter streak of earnings beats. With the stock trading 92% above its 200-day moving average and analyst price targets implying 74% upside, this report will determine whether IBRX's transformation story remains intact or if execution challenges are emerging.

ImmunityBio is a clinical-stage immunotherapy company focused on developing therapies for cancer and infectious diseases, with its lead product ANKTIVA...

Fundamentals

See More
  • Market Capitalization, $K 8,912,914
  • Shares Outstanding, K 1,047,346
  • Annual Sales, $ 113,290 K
  • Annual Income, $ -351,400 K
  • EBIT $ -256 M
  • EBITDA $ -241 M
  • 60-Month Beta 0.02
  • Price/Sales 71.74
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 107.26% (+8.74%)
  • Historical Volatility 90.38%
  • IV Percentile 54%
  • IV Rank 35.75%
  • IV High 182.84% on 01/20/26
  • IV Low 65.20% on 12/30/25
  • Expected Move (DTE 5) 0.91 (10.69%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 67,388
  • Volume Avg (30-Day) 29,006
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 650,791
  • Open Int (30-Day) 644,073
  • Expected Range 7.60 to 9.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 2
  • High Estimate $-0.08
  • Low Estimate $-0.08
  • Prior Year $-0.10
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.73 +26.45%
on 04/29/26
8.56 -0.58%
on 05/08/26
+1.53 (+21.92%)
since 04/08/26
3-Month
5.82 +46.22%
on 02/09/26
12.43 -31.54%
on 02/25/26
+2.46 (+40.66%)
since 02/06/26
52-Week
1.95 +336.41%
on 12/31/25
12.43 -31.54%
on 02/25/26
+6.42 (+307.18%)
since 05/08/25

Most Recent Stories

More News
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

NEW YORK , May 9, 2026 /PRNewswire/ --

IBRX : 8.51 (+9.66%)
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK and NEW ORLEANS , May 8, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial...

IBRX : 8.51 (+9.66%)
ImmunityBio's Commercial Ramp Now Carries the Weight of Its Entire Investment Thesis

Barchart Research What to Expect from IBRX Earnings IBRX Generated May 8, 2026 Current Price $8.51 EPS Estimate $$-0.08 Consensus Rating Strong Buy Average Move 7.74% ImmunityBio's Commercial Ramp Now...

IBRX : 8.51 (+9.66%)
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , May 8, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

IBRX : 8.51 (+9.66%)
IBRX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)

Did you buy IBRX securities between January 19, 2026, and March 24, 202 6?

IBRX : 8.51 (+9.66%)
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

SAN DIEGO , May 8, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities...

IBRX : 8.51 (+9.66%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX

NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX).  Such investors...

IBRX : 8.51 (+9.66%)
ImmunityBio: Q1 Earnings Snapshot

ImmunityBio: Q1 Earnings Snapshot

IBRX : 8.51 (+9.66%)
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

Q1 2026 Revenue Growth with Continued Strong Sales Momentum: $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 and up 15% from Q4 2025 ...

IBRX : 8.51 (+9.66%)
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misbranded Cancer Drug: Levi & Korsinsky

Notice to Pension Funds, Asset Managers, and Fiduciaries

IBRX : 8.51 (+9.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest...

See More

Key Turning Points

3rd Resistance Point 9.83
2nd Resistance Point 9.20
1st Resistance Point 8.85
Last Price 8.51
1st Support Level 7.87
2nd Support Level 7.24
3rd Support Level 6.89

See More

52-Week High 12.43
Last Price 8.51
Fibonacci 61.8% 8.43
Fibonacci 50% 7.19
Fibonacci 38.2% 5.95
52-Week Low 1.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.